These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 33721949)

  • 1. [Current status and controversy of neoadjuvant therapy in pancreatic cancer].
    Liu DX; Hu JS; Sun B
    Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(10):712-715. PubMed ID: 33721949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The value of extended surgery for pancreatic cancer in the context of neoadjuvant therapy].
    Zhang TP; Liu YZ; Cao Z
    Zhonghua Wai Ke Za Zhi; 2020 Jul; 58(7):481-485. PubMed ID: 32610414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Still no evidence for neoadjuvant therapy of pancreatic cancer].
    Strobel O; Büchler MW
    Chirurg; 2020 Jul; 91(7):596. PubMed ID: 32500215
    [No Abstract]   [Full Text] [Related]  

  • 4. [Neoadjuvant chemotherapy for resectable pancreatic cancer].
    Unno M
    Nihon Shokakibyo Gakkai Zasshi; 2020; 117(4):297-301. PubMed ID: 32281569
    [No Abstract]   [Full Text] [Related]  

  • 5. [Current consensus and controversy in neoadjuvant therapy for pancreatic cancer].
    Ou ZL; Li YX; Ji LD; Ke MJ
    Zhonghua Wai Ke Za Zhi; 2020 Feb; 58(2):99-104. PubMed ID: 32074807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evidence of Neoadjuvant Treatment for Pancreatic Cancer].
    Kawai M; Yamaue H
    Gan To Kagaku Ryoho; 2018 Oct; 45(10):1410-1414. PubMed ID: 30382034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Progress in neoadjuvant and transformation therapy of pancreatic cancer].
    Hu DD; Dai MH
    Zhonghua Wai Ke Za Zhi; 2017 Jan; 55(1):69-72. PubMed ID: 28056259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Indications and efficacy of neoadjuvant therapy for pancreatic cancer].
    Gou SM; Wu HS
    Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(10):716-721. PubMed ID: 33721950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nodal downstaging as a treatment goal for node-positive pancreatic cancer.
    Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS
    Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
    Barnes CA; Aldakkak M; Christians KK; Clarke CN; Dua K; George B; Ritch PS; Kamgar M; Hall WA; Kulkarni N; Erickson BA; Evans DB; Tsai S
    Surgery; 2020 Sep; 168(3):440-447. PubMed ID: 32641278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of neoadjuvant therapy in pancreatic cancer: a review.
    Russo S; Ammori J; Eads J; Dorth J
    Future Oncol; 2016 Mar; 12(5):669-85. PubMed ID: 26880384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of Resectability and Survival in Patients with Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment with FOLFIRINOX.
    Hu HJ; Li FY
    Ann Surg; 2018 Dec; 268(6):e95-e96. PubMed ID: 29864093
    [No Abstract]   [Full Text] [Related]  

  • 15. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Developments and controversies in neoadjuvant therapy for resectable pancreatic cancer].
    Bai XL; Li X; Liang TB
    Zhonghua Wai Ke Za Zhi; 2020 Jul; 58(7):486-489. PubMed ID: 32610415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of neoadjuvant therapy on the perioperative complications of pancreatic cancer].
    Shi S; Yu XJ
    Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(10):708-711. PubMed ID: 33721948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Call for better response evaluation after neoadjuvant therapy in pancreatic cancer.
    Zaharia C; Søreide K
    Br J Surg; 2023 Feb; 110(3):294-296. PubMed ID: 36630676
    [No Abstract]   [Full Text] [Related]  

  • 19. Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma.
    Schwarz L; Katz MH
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):727-40. PubMed ID: 26226907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.